Boston Scientific (NYSE:BSX) Cut to “Hold” at Daiwa Securities Group

Daiwa Securities Group downgraded shares of Boston Scientific (NYSE:BSX) from a strong-buy rating to a hold rating in a research note published on Wednesday morning,Zacks.com reports.

A number of other equities research analysts have also recently commented on the company. Jefferies Financial Group lowered their target price on Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. National Bank Financial set a $115.00 target price on Boston Scientific in a research note on Monday, February 2nd. Truist Financial lowered their target price on Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Thursday, April 23rd. Robert W. Baird decreased their price objective on Boston Scientific from $86.00 to $78.00 and set an “outperform” rating for the company in a report on Thursday, April 23rd. Finally, Sanford C. Bernstein reissued an “outperform” rating and issued a $112.00 price objective on shares of Boston Scientific in a report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $93.91.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $56.64 on Wednesday. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The stock’s fifty day simple moving average is $67.06 and its two-hundred day simple moving average is $84.72. Boston Scientific has a 1-year low of $56.05 and a 1-year high of $109.50. The stock has a market cap of $84.18 billion, a PE ratio of 23.70, a price-to-earnings-growth ratio of 1.06 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.68% and a net margin of 17.29%.The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same period last year, the business earned $0.75 EPS. The business’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, analysts forecast that Boston Scientific will post 3.38 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.34% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

Several large investors have recently added to or reduced their stakes in the company. Crown Wealth Group LLC grew its holdings in Boston Scientific by 4.7% during the 3rd quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock valued at $218,000 after buying an additional 100 shares in the last quarter. Claret Asset Management Corp grew its holdings in Boston Scientific by 4.4% during the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock valued at $234,000 after buying an additional 102 shares in the last quarter. Cary Street Partners Investment Advisory LLC grew its holdings in Boston Scientific by 5.1% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after buying an additional 103 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors grew its holdings in Boston Scientific by 2.3% during the 3rd quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 4,776 shares of the medical equipment provider’s stock valued at $466,000 after buying an additional 108 shares in the last quarter. Finally, Kera Capital Partners Inc. grew its holdings in Boston Scientific by 3.3% during the 3rd quarter. Kera Capital Partners Inc. now owns 3,407 shares of the medical equipment provider’s stock valued at $333,000 after buying an additional 109 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Institutional interest: hedge fund Lone Pine (Stephen Mandel) recently opened a new position in BSX, signaling some large investors view recent weakness as a buying opportunity. Stephen Mandel Opens New Position
• Positive Sentiment: Analyst conviction persists in places: media pieces note that the average brokerage recommendation still favors adding BSX — analysts continue to highlight long?term fundamentals despite recent headwinds. Wall Street Analysts Think Boston Scientific Is a Good Investment
• Neutral Sentiment: Investor attention and commentary: several outlets (Zacks, MSN, Yahoo) are amplifying debate about BSX’s outlook — this increases short?term volatility but is informational rather than a direct catalyst. Zacks: Attracting Investor Attention
• Negative Sentiment: Mounting securities?class?action notices and lead?plaintiff deadlines (May 4) from multiple law firms are creating legal risk and headline pressure; numerous firms are soliciting plaintiffs and investigating potential misstatements about market growth/competition. This is likely a near?term overhang. PR Newswire: Opportunity to Lead Securities Fraud Lawsuit Faruqi & Faruqi Reminder
• Negative Sentiment: Analyst downgrades and price?target cuts: several firms have trimmed targets (Argus cut its PT to $95; other outlets report an ~11% PT reduction to ~$90 and Daiwa moved BSX from strong?buy to hold). Those revisions reflect the company’s recent guidance/earnings and rising competitive pressures and are weighing on sentiment. Argus Price Target Cut Price Target Reduced

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.